Bioavailability of pyridoxal phosphate from enteric-coated tablets. I. Apparent critical dissolution pH and bioavailability of commercial products in humans.

Kaniwa, Nahoko; Ogata, Hiroyasu; Aoyagi, Nobuo; Koibuchi, Masanobu; Shibazaki, Toshio; Ejima, Akira; Takanashi, Seiji; Kono, Hiroshi; Suzuki, Hidetaka; Hinohara, Yoshikazu; Nakano, Hideki; Okazaki, Akira; Fujikura, Tadao; Igusa, Kazuo; Bessho, Sadao

doi:10.1248/cpb.33.4045

Cited by 9 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…as well [45]. The influence of formulation upon bioavailability is underlined by Kaniwa et al [46]. They compared the bio availability of 48 different enteric-coated and 5 sugar-coated PLP-containing tablets in 12 males (21 to 52 years of age).…”

Section: Pharmacokinetics In Blood Plasma After Oral or Intravenous Vmentioning

confidence: 99%

Pharmacokinetics of vitamin B6 supplements in humans.

Zempleni

1995

Journal of the American College of Nutrition

View full text Add to dashboard Cite

The use of vitamin B6 supplements is widespread today. Doses used are often elevated far above the physiological range and reach levels up to 600-fold higher than recommended dietary allowances for healthy people. While the toxic effects caused by chronic high doses of vitamin B6 have been described earlier, pharmacokinetic data on vitamin B6 supplements are rare. This article reviews the pharmacokinetic data of vitamin B6 from human subjects.

show abstract

Section: Pharmacokinetics In Blood Plasma After Oral or Intravenous Vmentioning

confidence: 99%

Pharmacokinetics of vitamin B6 supplements in humans.

Zempleni

1995

Journal of the American College of Nutrition

View full text Add to dashboard Cite

show abstract

“…All the formulations were prepared with similar blending time and compaction conditions. [2][3][4][5][6][7] The composition of the core tablets is shown in Table. 1.…”

Section: Preparation Of Core Tabletsmentioning

confidence: 99%

Development of Extended Release Formulations of Ilaprazole Tablets

Divya

Sreekanth

Satyavati

2019

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Extended release products are designed to release their medication in a controlled manner at a predetermined rate, duration, and location to achieve and maintain optimum therapeutic blood levels of a drug. The objective of the study is to formulate and evaluate Ilaprazole Controlled release tablets comparable to the innovator product. F1-F9 formulations were prepared using varying concentrations of super disintegrates like Crospovidone, Croscarmellose sodium and Sodium starch glycolate in different concentrations. Based on the hardness, friability, weight variation, drug content, F6 formulation was found to be optimised. The selected F6 formulation was sub coated with HPMC P 50 and followed by enteric coating with Acryl-EZE-80 (Eudragit L100-55). 3 formulations (F10-F12) were prepared by using coating. Among the three formulations, F11 formulation was found to be best. FTIR studies were carried out to find out drug and excipient compatibility studies, the studies revealed that there were no interactions. DSC studies also carried out to demonstrate any changes in physical forms of the drug molecule. Keywords: Ilaprazole, Extended release tablets, Crospovidone, Croscarmellose sodium, Sodium starch glycolate, HPMC P 50, Acryl-EZE-80.

show abstract

“…Similarly, certain groups of Azoles are acidunstable. For such types of drugs, enteric coating integrated to the formulation inclines to eschew the stomach's acidic exposure, distributing them instead to a fundamental pH environment (intestines pH 5.5 and above)where they do not degrade, and give their desired action 2 .The different release characteristics of the enteric polymers have profound impact upon the pharmacokinetic parameters of the drug 5,6 . An Ideal enteric polymer should possess a hydrophilic and hydrophobic monomeric unit.…”

Section: Introductionmentioning

confidence: 99%

An Overview on Sustained Release Enteric Coated Tablet of Pentoprazole

Singh¹,

Sharma²,

Dhakad³

2014

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Pantoprazole drug is utilized for treatment of gastric and duodenum ulcer, utilized as proton pump inhibitor, belongs to group of Benzimidazole. Pantoprazole drug undergoes through acidic medium of the stomach, can be coated with enteric coating polymer after that they will safely distribute the drug in the musculin intestine, for the degradation. Pantoprazole has been prepared by direct compression method utilizing variant excipient on different concentration like crosscarmellose sodium as disintegrating agent, dicalcium phosphate as diluents and mannitol. Direct compression is economic since it requires fewer unit operations, compare to wet granulation method. This direct compression method require less equipment, need low power consumption, less space, short duration, leading to low cost of tablets dosage form. The prepared tablets has been evaluated by different evaluation parameter like hardness, surface morphology, weight variation, friability, percentage yield, and it was found that the results comply with official standards. The in-vitro release has been evaluated utilizing pH 1.2 acidic buffer and pH 6.8 phosphate buffer. The in-vitro release study showed that the prepared and evaluated pantoprazole tablets are capable to sustain release drug in the intestine.

show abstract

Bioavailability of pyridoxal phosphate from enteric-coated tablets. I. Apparent critical dissolution pH and bioavailability of commercial products in humans.

Cited by 9 publications

References 0 publications

Pharmacokinetics of vitamin B6 supplements in humans.

Pharmacokinetics of vitamin B6 supplements in humans.

Development of Extended Release Formulations of Ilaprazole Tablets

An Overview on Sustained Release Enteric Coated Tablet of Pentoprazole

Contact Info

Product

Resources

About